Patents by Inventor Nemichand B. Jain

Nemichand B. Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220211668
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 7, 2022
    Inventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
  • Patent number: 11160786
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: November 2, 2021
    Assignee: APRECIA PHARMACEUTICALS LLC
    Inventors: Jules Jacob, Norman Coyle, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
  • Publication number: 20170258763
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
    Type: Application
    Filed: May 16, 2017
    Publication date: September 14, 2017
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
  • Publication number: 20170202807
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.
    Type: Application
    Filed: April 4, 2017
    Publication date: July 20, 2017
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: JULES JACOB, NORMAN COYLE, THOMAS G. WEST, DONALD C. MONKHOUSE, HENRY L. SURPRENANT, NEMICHAND B. JAIN
  • Patent number: 9669009
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: June 6, 2017
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Norman Coyle, Thomas G. West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
  • Publication number: 20160220534
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
    Type: Application
    Filed: April 11, 2016
    Publication date: August 4, 2016
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Norman COYLE, Thomas G. WEST, Donald C. MONKHOUSE, Henry L. SURPRENANT, Nemichand B. JAIN
  • Patent number: 9339489
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: May 17, 2016
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Norman Coyle, Thomas G West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
  • Publication number: 20140271862
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
    Type: Application
    Filed: May 15, 2014
    Publication date: September 18, 2014
    Applicant: APRECIA PHARMACEUTICALS COMPANY
    Inventors: Jules JACOB, Norman COYLE, Thomas G. WEST, Donald C. MONKHOUSE, Henry L. SURPRENANT, Nemichand B. JAIN
  • Patent number: 7135465
    Abstract: Extended dosage forms of stavudine are provided comprising beadlets formed by extrusion-spheronization and coated with a seal coating. The beadlets are also coated with a modified release coating such that a hard gelatin capsule containing such beadlets will provide blood levels of stavudine over approximately 24 hours. The beadlets are prepared from a dry blend of stavudine, a spheronizing agent, a suitable diluent and a stabilizing amount of magnesium stearate. The magnesium stearate, in contrast to other similar pharmaceutical adjuncts, has been found to stabilize stavudine against degradation due to hydrolysis in the presence of the limited amount of water necessary for the extrusion-spheronization process. Also included in the scope of the invention are hard gelatin capsules containing, in addition to the stavudine beadlets, similar beadlets containing other therapeutic agents utilized to treat retroviral infections.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: November 14, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Abramowitz, Denise M. O'Donoghue, Nemichand B. Jain
  • Publication number: 20040005358
    Abstract: A modified-release vasopeptidase inhibitor formulation is provided which is capable of releasing vasopeptidase inhibitor, preferably omapatrilat or gemopatrilat, in a manner to provide therapeutically effective NEP inhibitory activity and therapeutically effective ACE inhibitory activity, in a balanced manner, for a predetermined duration to lower blood pressure and/or treat heart failure. In a preferred formulation, the NEP inhibitory activity and ACE inhibitory activity have balanced release characteristics.
    Type: Application
    Filed: April 21, 2003
    Publication date: January 8, 2004
    Inventors: Peter H. Slugg, Nemichand B. Jain, Rajesh Krishna, Robert L. Jerzewski, Ronald L. Smith, Jatin M. Patel, Bimal K. Malhotra
  • Publication number: 20020034546
    Abstract: A pharmaceutical composition is provided which is useful for cholesterol lowering and reducing the risk of a myocardial infarction, which includes a statin, such as pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin or fluvastatin, in combination with aspirin, in a manner to minimize interaction of aspirin with the statin and minimize side effects of aspirin. A method for lowering cholesterol and reducing risk of a myocardial infarction employing such composition is also provided.
    Type: Application
    Filed: April 2, 2001
    Publication date: March 21, 2002
    Inventors: Ismat Ullah, Nemichand B. Jain
  • Publication number: 20020002147
    Abstract: Extended dosage forms of stavudine are provided comprising beadlets formed by extrusion-spheronization and coated with a seal coating. The beadlets are also coated with a modified release coating such that a hard gelatin capsule containing such beadlets will provide blood levels of stavudine over approximately 24 hours. The beadlets are prepared from a dry blend of stavudine, a spheronizing agent, a suitable diluent and a stabilizing amount of magnesium stearate. The magnesium stearate, in contrast to other similar pharmaceutical adjuncts, has been found to stabilize stavudine against degradation due to hydrolysis in the presence of the limited amount of water necessary for the extrusion-spheronization process. Also included in the scope of the invention are hard gelatin capsules containing, in addition to the stavudine beadlets, similar beadlets containing other therapeutic agents utilized to treat retroviral infections.
    Type: Application
    Filed: March 29, 2001
    Publication date: January 3, 2002
    Inventors: Robert Abramowitz, Denise M. O'Donoghue, Nemichand B. Jain
  • Patent number: 6235311
    Abstract: A pharmaceutical composition is provided which is useful for cholesterol lowering and reducing the risk of a myocardial infarction, which includes a statin, such as pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin or fluvastatin, in combination with aspirin, in a manner to minimize interaction of aspirin with the statin and minimize side effects of aspirin. A method for lowering cholesterol and reducing risk of a myocardial infarction employing such composition is also provided.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: May 22, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ismat Ullah, Nemichand B. Jain
  • Patent number: 5536507
    Abstract: A three component pharmaceutical formulation of one or more pharmacologically active substances such that greater than 80% of the pharmacologically active substance will be released in the large intestine. The first component comprises the pharmacologically active substance, microcrystalline cellulose, a pH-sensitive polymer, and optionally an osmotic agent. The second component is a delayed release coating, and the third component is an enteric coating.
    Type: Grant
    Filed: June 24, 1994
    Date of Patent: July 16, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Abramowitz, Sunanda A. Ranadive, Sailesh A. Varia, Nemichand B. Jain
  • Patent number: 5506248
    Abstract: An ifetroban composition is provided which has good dissolution properties even on aging, when dispersed in water has a pH of at least 7 and includes a salt of ifetroban, one or more basifying agents, such as magnesium oxide or calcium carbonate, and where in tablet form includes one or more fillers such as mannitol and/or microcrystalline cellulose, one or more disintegrating agents such as crospovidone, one or more lubricants such as magnesium stearate, optionally one or more glidants such as colloidal silicon dioxide, one or more binders such as pregelatinized starch (dry binder) or polyvinyl-pyrrolidone (wet binder) and optionally a film coating containing a film former such as hydroxypropyl cellulose and a plasticizer such as 1,2,3-propanetriol triacetate.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: April 9, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Faranak Nikfar, Abu T. M. Serajuddin, Robert L. Jerzewski, Nemichand B. Jain
  • Patent number: 5180589
    Abstract: A pharmaceutical composition is provided which has excellent stability, when dispersed in water has a pH of at least about 9, and includes a medicament which is sensitive to a low pH environment such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.
    Type: Grant
    Filed: May 20, 1991
    Date of Patent: January 19, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Yatindra M. Joshi, Pierina Chiesa, Nemichand B. Jain
  • Patent number: 5158777
    Abstract: A formulation comprising captopril within an enteric or delayed release coated pH stable core combined with additional captopril that is available for immediate release following administration.
    Type: Grant
    Filed: August 16, 1991
    Date of Patent: October 27, 1992
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Robert Abramowitz, Yatinda M. Joshi, Nemichand B. Jain
  • Patent number: 5030447
    Abstract: A pharmaceutical compositions is provided which has excellent stability, when dispersed in water has a pH of at least about 9, and includes a medicament which is sensitive to a low pH environment such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as mirocrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder), one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.
    Type: Grant
    Filed: March 31, 1988
    Date of Patent: July 9, 1991
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Yatindra M. Joshi, Pierina Chiesa, Nemichand B. Jain
  • Patent number: 5006344
    Abstract: Shelf stable tablets containing fosinopril sodium are prepared by employing either sodium stearyl fumarate or hydrogenated vegetable oil as the lubricant. The tablets can contain conventional excipients such as fillers, binders, and disintegrants as well as an optional diuretic.
    Type: Grant
    Filed: June 26, 1990
    Date of Patent: April 9, 1991
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Robert L. Jerzewski, Thomas M. Wong, Lewis J. Gryziewicz, Nemichand B. Jain, Ajit B. Thakur
  • Patent number: 4808413
    Abstract: A pharmaceutical composition is provided which is in the form of a plurality of beadlets, adapted to be filled into pharmaceutical hard shell capsules, or compressed into tablets, which beadlets are formed of a pharmaceutical such as an ACE inhibitor, for example, captopril, a beta-blocker such as nadolol, propranolol or atenolol, a calcium channel blocker such as diltiazem or nifedipine or other pharmaceuticals including combinations thereof, binder such as microcrystalline cellulose, and at least 5% by weight of an acid processing aid, such as citric acid, which imparts plasticity to the wet mass needed for efficient extrusion and spheronization. A method for forming beadlets is also provided which includes the steps of extruding a composition as described above, and subjecting the resulting extrudate to a spheronization step wherein an acid processing aid such as citric acid is employed to improve processing and form improved beadlets.
    Type: Grant
    Filed: December 31, 1987
    Date of Patent: February 28, 1989
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Yatindra M. Joshi, William R. Bachman, Nemichand B. Jain